Akari Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AKTX and other ETFs, options, and stocks.

About AKTX

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.

CEO

Abizer Gaslightwala

CEOAbizer Gaslightwala

Employees

Employees9

Headquarters

Boston, Massachusetts

HeadquartersBoston, Massachusetts

Founded

2004

Founded2004

Employees

Employees9

AKTX Key Statistics

Market cap

32.63M

Market cap32.63M

Price-Earnings ratio

-0.16

Price-Earnings ratio-0.16

Dividend yield

—

Dividend yield—

Average volume

13.31K

Average volume13.31K

High today

$1.16

High today$1.16

Low today

$1.10

Low today$1.10

Open price

$1.14

Open price$1.14

Volume

47.36K

Volume47.36K

52 Week high

$4.40

52 Week high$4.40

52 Week low

$0.85

52 Week low$0.85

Akari Therapeutics

Why Robinhood?

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. Show more

AKTX Key Statistics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor.